ArticleEcancermedicalscience2025
Analysing the clinical outcomes between FIGO 2009 and 2023 staging for endometrial cancer-a single institution retrospective study.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The latest International Federation of Gynaecology and Obstetrics (FIGO) staging for endometrial cancer incorporated molecular profiles and histopathological factors into the basic staging framework. This study was done to determine its implications when applied in real-world clinical practice. The main objectives were to analyse the stage shifts and determine the stage-wise 3-year overall survival (OS) and disease-free survival (DFS) between the two staging systems. It was a single-institution retrospective study that included all Endometrial cancer patients who underwent surgery between January 2015 and June 2021. Cases that underwent primary or incomplete surgery elsewhere and cases with histological types of cancer not included in FIGO 2023 staging were excluded from the study. All patients were staged according to FIGO 2009 and 2023 staging for endometrial cancer. This study found most stage shifts among stage I cases; based on aggressive histology, 33.8% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.